Sanofi - ADR (SNY) News
Filter SNY News Items
SNY News Results
|Loading, please wait...|
SNY News Highlights
- For SNY, its 30 day story count is now at 53.
- Over the past 23 days, the trend for SNY's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
- The most mentioned tickers in articles about SNY are MRNA, BIO and LAW.
Latest SNY News From Around the Web
Below are the latest news stories about Sanofi that investors may wish to consider to help them evaluate SNY as an investment opportunity.
Dr. Cedric Dark, Assistant Professor at Baylor College of Medicine & Board Member with Doctors for America, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Sanofi: New Dupixent (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
New Dupixent (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV More than 30 presentations reinforce the role of Dupixe
KADMON HOLDINGS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Kadmon Holdings, Inc. (NASDAQ: KDMN) to Sanofi (NASDAQ: SNY). Under the terms of the proposed transaction, shareholders of Kadmon will receive only $9.50 in cash for each share of Kadmon that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV More than 30 presentations reinforce the role of Dupixent in targeting IL-4 and IL-13, key drivers of the type 2 inflammation underlying atopic dermatitis in children, adolescents, and adults Results provide insight into the clinical and real-world experience of Dupixent on key disease measures including itch, disease severity, sleep and anxietyDupixent pr
Global Vaccines Market to Grow in Size with a Healthy CAGR | Players Merck & Co., Inc., Bharat Biotech, GlaxoSmithKline plc, Sanofi
A believable Global Vaccines Market report presents top to bottom examination of the market for estimating income, return on investment (ROI) and developing business strategies. Here, market analysis makes an assessment of the expected rise, growth or fall of the
Prion Disease Treatment Market Projected to Exhibit a Double-Digit CAGR between 2021 and 2028 | Elite Pharma, Ionis Pharma, Teva, Mylan, Novartis, Abbott, Merck, Pfizer, Sanofi
Overview of the Global Prion Disease Treatment Market: Global Prion Disease Treatment Market report is a skilful and deep analysis of the present situation and challenges. This report focuses on the key drivers, restraints, Market opportunities, threats and risks for Market major
Buccal Drug Delivery Market with Attractiveness, Competitive Landscape and Top Key Players (GSK, Teva, Pfizer, AstraZeneca, Roche, Sanofi, Bayer) | Forecasts to 2028
Global Buccal Drug Delivery Market Synopsis: Buccal Drug Delivery Market survey report analyses the changing trends in the industry. This Market report is a comprehensive background analysis of the Healthcare industry which includes an assessment of the parental Market. In this
Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors
Ms. Corzo brings a 25+ year successful track record in biopharma, excelling in oncology drug development with Takeda, Sanofi Genzyme, and Eli Lilly
Suzanne Judd, Ph.D., Epidemiologist at the University of Alabama at Birmingham School of Public Health, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
In the past five years, British firms have faced Brexit, a crash in the value of the pound and long coronavirus lockdowns – but that has not hindered returns for some businesses.